Neutrophil LECAM-1 as indicator of neutrophil activation
Patent 5316913 Issued on May 31, 1994. Estimated Expiration Date: 
September 6, 2011. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 6, 2011. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesTherapeutic and diagnostic methods using soluble T cell surface molecules Patent #: 5006459 InventorsAssigneeApplicationNo. 755749 filed on 09/06/1991US Classes:435/7.24, Leukocyte (e.g., lymphocyte, granulocyte, monocyte, etc.)435/7.94, Sandwich assay435/975, KIT436/518, INVOLVING AN INSOLUBLE CARRIER FOR IMMOBILIZING IMMUNOCHEMICALS436/536, INVOLVING IMMUNE COMPLEX FORMED IN LIQUID PHASE436/548Monoclonal antibodyExaminersPrimary: Saunders, DavidAttorney, Agent or FirmInternational ClassG01N 033/543AbstractMethods and compositions are provided for determining neutrophil activation in a mammalian host by detecting the presence of shed LECAM-1 in the blood. By employing a monoclonal antibody which binds to a common epitope of lymphocyte and neutrophil LECAM-1 and a monoclonal antibody which binds to a sialylated Lewis X epitope which distinguishes between neutrophil and lymphocyte LECAM-1, the level of neutrophil activation can be determined. Various immunoassay protocols may be employed which detect the binding of the two antibodies to a common antigen.Other References
|
| ||||||||||||||
